A STUDY OF PCI-32765 (IBRUTINIB) IN COMBINATION WITH EITHER BENDAMUSTINE AND RITUXIMAB OR RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE IN PARTICIPANTS WITH PREVIOUSLY TREATED INDOLENT NON-HODGKIN LYMPHOMA: